Joshua Seinfeld
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Joshua Seinfeld has a total of 106 co-authors. Here are the top co-authors by number of shared publications:
- Christopher Roark
Department of Neurosurgery, University of Colorado Anschutz Medical Campus, Aurora, USA
5 shared publications - Ramesh Grandhi
Department of Neurosurgery, Clinical Neurosciences Center, University of Utah, Salt Lake City, Utah, USA
3 shared publications - Blake Wittenberg
Department of Neurosurgery, University of Colorado Anschutz Medical Campus School of Medicine, Aurora, Colorado, USA
2 shared publications David Case
Department of Neurosurgery, University of Colorado School of Medicine, Aurora, CO, USA
2 shared publications- David E. Case
Department of Neurosurgery, University of Colorado Anschutz Medical Campus, Aurora, USA
2 shared publications - Zach Folzenlogen
Department of Neurosurgery, University of Colorado Anschutz Medical Campus, Aurora, USA
2 shared publications
Latest Publications
- 2 July 2026
- Published by Springer Nature in Neuroradiology
- Vol. 68  (9) , 1-10
Pre-existing intracranial arterial stenosis independently predicts delayed cerebral ischemia after aneurysmal subarachnoid hemorrhage
Purpose Delayed cerebral ischemia (DCI) remains a significant cause of morbidity and mortality following aneurysmal subarachnoid hemorrhage (aSAH). Despite identification of numerous predictors, risk remains variable even among patients with similar hemorrhage severity suggesting presence of unrecognized modifiers. One factor receiving little attention is intracranial arterial disease (ICAD): stenosis and calcification. We aim to examine their additive impacts to known modifiers. Methods We analyzed 526 patients with aSAH treated at a single, tertiary care center between 2015 and 2025. DCI was defined as new neurologic deficits and/or new cerebral infarction ≥ 48 h from hemorrhage not explained by other etiologies. Stenosis (≥ 25% of luminal diameter) and calcification (CTA hyperdensity ≥ 100 HU) were assessed in all arteries including and distal to the petrous ICA on admission CTA. Multivariable logistic regressions were used to determine independent associations with DCI. For easy clinical applicability, ICAD was dichotomized as presence vs. absence. Results Among 526 patients with aSAH, 440 survived ≥ 48 h and were included (median age = 56 IQR [45–64], 63.7% female). 132/440 (30.1%) developed DCI. DCI was associated with significantly worse outcomes (median mRS DCI: 4, No DCI 2, p < 0.001). Stenosis, not calcification, was an independent predictor of DCI (aOR:3.556, 95%CI: 1.90–6.65, p < 0.001). Vasospasm significantly correlated with DCI (OR:5.89, 95%CI: 3.62–9.57, p < 0.001), and more common in patients with stenosis (aOR:2.391 95%CI: 1.240–4.608, p < 0.001). Conclusion Pre-existing ICAD confers substantial, independent DCI risk after aSAH, enhancing rather than competing with traditional predictors. This suggests that baseline cerebrovascular integrity meaningfully predicts ischemic vulnerability following hemorrhage.
- 2 July 2026
- Published by Springer Nature in Neuroradiology
- Vol. 68  (9) , 1-10
Pre-existing intracranial arterial stenosis independently predicts delayed cerebral ischemia after aneurysmal subarachnoid hemorrhage
Purpose Delayed cerebral ischemia (DCI) remains a significant cause of morbidity and mortality following aneurysmal subarachnoid hemorrhage (aSAH). Despite identification of numerous predictors, risk remains variable even among patients with similar hemorrhage severity suggesting presence of unrecognized modifiers. One factor receiving little attention is intracranial arterial disease (ICAD): stenosis and calcification. We aim to examine their additive impacts to known modifiers. Methods We analyzed 526 patients with aSAH treated at a single, tertiary care center between 2015 and 2025. DCI was defined as new neurologic deficits and/or new cerebral infarction ≥ 48 h from hemorrhage not explained by other etiologies. Stenosis (≥ 25% of luminal diameter) and calcification (CTA hyperdensity ≥ 100 HU) were assessed in all arteries including and distal to the petrous ICA on admission CTA. Multivariable logistic regressions were used to determine independent associations with DCI. For easy clinical applicability, ICAD was dichotomized as presence vs. absence. Results Among 526 patients with aSAH, 440 survived ≥ 48 h and were included (median age = 56 IQR [45–64], 63.7% female). 132/440 (30.1%) developed DCI. DCI was associated with significantly worse outcomes (median mRS DCI: 4, No DCI 2, p < 0.001). Stenosis, not calcification, was an independent predictor of DCI (aOR:3.556, 95%CI: 1.90–6.65, p < 0.001). Vasospasm significantly correlated with DCI (OR:5.89, 95%CI: 3.62–9.57, p < 0.001), and more common in patients with stenosis (aOR:2.391 95%CI: 1.240–4.608, p < 0.001). Conclusion Pre-existing ICAD confers substantial, independent DCI risk after aSAH, enhancing rather than competing with traditional predictors. This suggests that baseline cerebrovascular integrity meaningfully predicts ischemic vulnerability following hemorrhage.
- Open Access
- 10 July 2025
- Published by Wolters Kluwer Health in Neurosurgery
- Vol. 98  (2) , 464-473
The Silk Vista Baby Study: A Multicenter Aneurysm Report From North America and Europe
BACKGROUND AND OBJECTIVES: The Silk Vista Baby (SVB) flow diverter (FD) stent (Balt SAS) is the first device designed for treating distally located brain aneurysms. It can be delivered through a 0.017-inch ID microcatheter, enabling access to small, distal vessels. The aim of this study was to evaluate the effectiveness, safety, technical success, occlusion rate, and clinical outcomes of the SVB device. METHODS: This retrospective, multicenter study included data from 18 centers from November 2023 to September 2024. Procedures were performed by experienced neurointerventionalists following institutional standards of care. Outcomes analyzed included effectiveness, safety, and aneurysm occlusion rates. Descriptive analyses and Pearson χ 2 or Independent t -Test were used for statistical evaluation. RESULTS: A total of 95 patients, mean age 55.4 years, were included. A total of 31% of aneurysms were ruptured at admission. Most (58.3%) were located in the anterior circulation, and 45% had previous treatment, mainly coiling (69.4%). Complication rates were higher for ruptured aneurysms (24.1%) compared with unruptured ones (9.2%). Two deaths occurred, 1 (1.1%) related to the procedure. At discharge, 87% of patients had modified Rankin Scale ≤2. The latest follow-up showed overall complete/near-complete occlusion rates of 76.1%, with 81.14% for ruptured and 73.43% for unruptured aneurysms. Technical success was higher in unruptured cases (100% vs 93.1%). CONCLUSION: Our case series demonstrated the efficacy of the SVB with a high rate of technical success. The occlusion rates for ruptured cases are comparable with those of other FDs. However, the rates are lower for unruptured cases. This discrepancy is likely due to the characteristics of the aneurysms, particularly in the presence of side branches in bifurcation lesions. The SVB safety profile is similar to other FDs in unruptured cases, while the ruptured group presented more complications.
- 10 July 2025
- Published by Wolters Kluwer Health in Neurosurgery
- Vol. 98  (2) , 464-473
Open AccessThe Silk Vista Baby Study: A Multicenter Aneurysm Report From North America and Europe
BACKGROUND AND OBJECTIVES: The Silk Vista Baby (SVB) flow diverter (FD) stent (Balt SAS) is the first device designed for treating distally located brain aneurysms. It can be delivered through a 0.017-inch ID microcatheter, enabling access to small, distal vessels. The aim of this study was to evaluate the effectiveness, safety, technical success, occlusion rate, and clinical outcomes of the SVB device. METHODS: This retrospective, multicenter study included data from 18 centers from November 2023 to September 2024. Procedures were performed by experienced neurointerventionalists following institutional standards of care. Outcomes analyzed included effectiveness, safety, and aneurysm occlusion rates. Descriptive analyses and Pearson χ 2 or Independent t -Test were used for statistical evaluation. RESULTS: A total of 95 patients, mean age 55.4 years, were included. A total of 31% of aneurysms were ruptured at admission. Most (58.3%) were located in the anterior circulation, and 45% had previous treatment, mainly coiling (69.4%). Complication rates were higher for ruptured aneurysms (24.1%) compared with unruptured ones (9.2%). Two deaths occurred, 1 (1.1%) related to the procedure. At discharge, 87% of patients had modified Rankin Scale ≤2. The latest follow-up showed overall complete/near-complete occlusion rates of 76.1%, with 81.14% for ruptured and 73.43% for unruptured aneurysms. Technical success was higher in unruptured cases (100% vs 93.1%). CONCLUSION: Our case series demonstrated the efficacy of the SVB with a high rate of technical success. The occlusion rates for ruptured cases are comparable with those of other FDs. However, the rates are lower for unruptured cases. This discrepancy is likely due to the characteristics of the aneurysms, particularly in the presence of side branches in bifurcation lesions. The SVB safety profile is similar to other FDs in unruptured cases, while the ruptured group presented more complications.
- 10 December 2023
- Published by SAGE Publications in The Neurohospitalist
- Vol. 14  (2) , 182-185
Clinical Decision Support for Patients Presenting With Large Vessel Occlusion
A single center had a collaborative, multidisciplinary review to determine how to best implement new acute ischemic stroke trials involving large vessel occlusions. A flow diagram process map was created for clinical decision support. Patients were divided into four groups based upon size of infarct and timing of presentation. The process map, available in the electronic health record (EHR) for clinicians to reference, guides the selection of patients for endovascular therapy with neuroimaging. In addition, the process map offers guidance for discussions with families and patients experiencing large vessel occlusions with both small and large core infarcts. This manuscript describes the process of creating the process map through a multidisciplinary review and discussion, with points of controversy and how these were addressed.
- 10 December 2023
- Published by SAGE Publications in The Neurohospitalist
- Vol. 14  (2) , 182-185
Clinical Decision Support for Patients Presenting With Large Vessel Occlusion
A single center had a collaborative, multidisciplinary review to determine how to best implement new acute ischemic stroke trials involving large vessel occlusions. A flow diagram process map was created for clinical decision support. Patients were divided into four groups based upon size of infarct and timing of presentation. The process map, available in the electronic health record (EHR) for clinicians to reference, guides the selection of patients for endovascular therapy with neuroimaging. In addition, the process map offers guidance for discussions with families and patients experiencing large vessel occlusions with both small and large core infarcts. This manuscript describes the process of creating the process map through a multidisciplinary review and discussion, with points of controversy and how these were addressed.
- Open Access
- 11 September 2023
- Published by Wolters Kluwer Health in Neurosurgery Practice
- Vol. 4  (4) , e00060
Time-Dosed Stereotactic Radiosurgery for the Treatment of Cerebral Arteriovenous Malformations: An Early Institution Experience and Case Series
BACKGROUND AND OBJECTIVES: Stereotactic radiosurgery (SRS) is an effective treatment modality used by neurosurgeons to treat cerebral arteriovenous malformations (AVMs), particularly for treating AVMs 10 cm3). We introduce a novel refinement called time-dosed SRS for the treatment of large-volume AVMs or AVMs located in eloquent areas. This study aims to detail treatment parameters, outcomes, and complications associated with time-dosed SRS in our early experience study. METHODS: We retrospectively reviewed all patients treated using time-dosed SRS at our institution. Data, including AVM location, history of hemorrhage, history of intervention, AVM volume, Spetzler-Martin grade, presence of residual disease, and occurrence of postprocedural complications, were collected. RESULTS: Sixteen patients were included. The median total AVM volumes treated were 9.64 cm3 (0.92-46.2 cm3) and 13.2 cm3 (3.0-42.2 cm3) in adults and children, respectively. The median margin doses for adults and children at each of the 3 stages were 10 Gy, 10 Gy (8-10 Gy) and 9 Gy (8-10 Gy), and 10 Gy, 10 Gy (9-10 Gy), and 10 Gy (8-10 Gy), respectively. The median total dose delivered was 29 Gy (27-30 Gy) in adults and 30 Gy (28-30 Gy) in children. The median radiological follow-up length was 35 months (9-62 months) in adults and 31 months (4-72 months) in pediatric patients. Complete obliteration was confirmed by cerebral angiogram in 6 adult patients and 1 pediatric patient. One adult patient and 2 pediatric patients suffered radiation-related toxicity. No patients suffered postprocedural hemorrhage. CONCLUSION: Time-dosed SRS seems to be effective for treating large AVMs or those in highly eloquent areas, with a low rate of complications.
- 11 September 2023
- Published by Wolters Kluwer Health in Neurosurgery Practice
- Vol. 4  (4) , e00060
Open AccessTime-Dosed Stereotactic Radiosurgery for the Treatment of Cerebral Arteriovenous Malformations: An Early Institution Experience and Case Series
BACKGROUND AND OBJECTIVES: Stereotactic radiosurgery (SRS) is an effective treatment modality used by neurosurgeons to treat cerebral arteriovenous malformations (AVMs), particularly for treating AVMs 10 cm3). We introduce a novel refinement called time-dosed SRS for the treatment of large-volume AVMs or AVMs located in eloquent areas. This study aims to detail treatment parameters, outcomes, and complications associated with time-dosed SRS in our early experience study. METHODS: We retrospectively reviewed all patients treated using time-dosed SRS at our institution. Data, including AVM location, history of hemorrhage, history of intervention, AVM volume, Spetzler-Martin grade, presence of residual disease, and occurrence of postprocedural complications, were collected. RESULTS: Sixteen patients were included. The median total AVM volumes treated were 9.64 cm3 (0.92-46.2 cm3) and 13.2 cm3 (3.0-42.2 cm3) in adults and children, respectively. The median margin doses for adults and children at each of the 3 stages were 10 Gy, 10 Gy (8-10 Gy) and 9 Gy (8-10 Gy), and 10 Gy, 10 Gy (9-10 Gy), and 10 Gy (8-10 Gy), respectively. The median total dose delivered was 29 Gy (27-30 Gy) in adults and 30 Gy (28-30 Gy) in children. The median radiological follow-up length was 35 months (9-62 months) in adults and 31 months (4-72 months) in pediatric patients. Complete obliteration was confirmed by cerebral angiogram in 6 adult patients and 1 pediatric patient. One adult patient and 2 pediatric patients suffered radiation-related toxicity. No patients suffered postprocedural hemorrhage. CONCLUSION: Time-dosed SRS seems to be effective for treating large AVMs or those in highly eloquent areas, with a low rate of complications.
- Open Access
- 30 July 2023
- Published by BMJ
- Vol. 15  (Suppl 1) , A29.1-A29
O-035 Endovascular treatment of cerebral venous thrombosis involving the deep venous system
Introduction Cerebral venous thrombosis (CVT) accounts for a small percentage of all strokes. While the superior sagittal sinus is the most common location, a subset of CVT involves the deep venous system - the internal cerebral veins, vein of Galen, basal vein of Rosenthal, and thalamostriate veins. Deep CVT can cause thalamic and basal ganglia edema, hemorrhage, and strokes, resulting in disorders of consciousness and subsequent death or dependency. While anticoagulation is the mainstay therapy for CVT, patients with worsening neurologic examinations, strokes, or intracerebral hemorrhage (ICH) may benefit from endovascular therapy and recanalization of the affected vessels. This is complicated in the deep veins by difficult catheterization due to small, fragile vessels. We hypothesize that endovascular treatment of the superficial venous sinuses or the straight sinus alone, without catheterization of deep veins, can result in apparent recanalization of the deep venous sinuses resulting in improved radiologic and clinical outcomes. Materials/Methods We queried our interventional radiology (IR) database from January 1, 2010 - February 23, 2021 for patients with CVT. This returned a total of 5599 patient encounters containing the search terms, of which 43 had undergone endovascular treatment for CVT. 31 of these patients had venous thrombosis in the superficial sinuses only, while 12 patients had venous thrombosis involving the deep venous system. Results The 12 patients whose CVT involved deep veins and who underwent endovascular intervention had the following demographics. All 12 patients underwent intervention due to clinical and/or radiographic worsening despite adequate heparin infusions. 4 patients underwent catheterization of the straight sinus. All other interventions were in the superficial venous sinuses only. All 12 patients with deep venous involvement ultimately had recanalization of the deep system. Modified Rankin scale at discharge was an average of 2.2 (range 0-5). Conclusions Although deep venous involvement of CVT is uncommon, these patients are at risk of quickly becoming critically ill with an elevated rate of death or dependency. Although these patients may develop stroke, hemorrhage, or neurologic decline prompting consideration of endovascular therapy, the deep cerebral venous system is not easily accessible with catheters due to small lumens and risk of perforation. It has been proposed that deep cerebral veins may have a higher chance of recanalization if venous thrombus burden is reduced in other parts of the dural venous sinuses. Current literature has not fully explored the association between endovascular treatment of the superficial dural venous sinuses and deep venous flow. Our study shows that endovascular recanalization of the superficial venous sinuses and/or straight sinus can subsequently result in recanalization of the deep veins and improve radiologic and clinical outcomes. Prospective trials are still needed to provide further evidence of safety and efficacy. Disclosures B. Morel: None. J. Hoffman: None. Z. Folzenlogen: None. C. Roark: None. J. Seinfeld: None. D. Case: None.
- 30 July 2023
- Published by BMJ
- Vol. 15  (Suppl 1) , A29.1-A29
Open AccessO-035 Endovascular treatment of cerebral venous thrombosis involving the deep venous system
Introduction Cerebral venous thrombosis (CVT) accounts for a small percentage of all strokes. While the superior sagittal sinus is the most common location, a subset of CVT involves the deep venous system - the internal cerebral veins, vein of Galen, basal vein of Rosenthal, and thalamostriate veins. Deep CVT can cause thalamic and basal ganglia edema, hemorrhage, and strokes, resulting in disorders of consciousness and subsequent death or dependency. While anticoagulation is the mainstay therapy for CVT, patients with worsening neurologic examinations, strokes, or intracerebral hemorrhage (ICH) may benefit from endovascular therapy and recanalization of the affected vessels. This is complicated in the deep veins by difficult catheterization due to small, fragile vessels. We hypothesize that endovascular treatment of the superficial venous sinuses or the straight sinus alone, without catheterization of deep veins, can result in apparent recanalization of the deep venous sinuses resulting in improved radiologic and clinical outcomes. Materials/Methods We queried our interventional radiology (IR) database from January 1, 2010 - February 23, 2021 for patients with CVT. This returned a total of 5599 patient encounters containing the search terms, of which 43 had undergone endovascular treatment for CVT. 31 of these patients had venous thrombosis in the superficial sinuses only, while 12 patients had venous thrombosis involving the deep venous system. Results The 12 patients whose CVT involved deep veins and who underwent endovascular intervention had the following demographics. All 12 patients underwent intervention due to clinical and/or radiographic worsening despite adequate heparin infusions. 4 patients underwent catheterization of the straight sinus. All other interventions were in the superficial venous sinuses only. All 12 patients with deep venous involvement ultimately had recanalization of the deep system. Modified Rankin scale at discharge was an average of 2.2 (range 0-5). Conclusions Although deep venous involvement of CVT is uncommon, these patients are at risk of quickly becoming critically ill with an elevated rate of death or dependency. Although these patients may develop stroke, hemorrhage, or neurologic decline prompting consideration of endovascular therapy, the deep cerebral venous system is not easily accessible with catheters due to small lumens and risk of perforation. It has been proposed that deep cerebral veins may have a higher chance of recanalization if venous thrombus burden is reduced in other parts of the dural venous sinuses. Current literature has not fully explored the association between endovascular treatment of the superficial dural venous sinuses and deep venous flow. Our study shows that endovascular recanalization of the superficial venous sinuses and/or straight sinus can subsequently result in recanalization of the deep veins and improve radiologic and clinical outcomes. Prospective trials are still needed to provide further evidence of safety and efficacy. Disclosures B. Morel: None. J. Hoffman: None. Z. Folzenlogen: None. C. Roark: None. J. Seinfeld: None. D. Case: None.
- Open Access
- 30 July 2023
- Published by BMJ
- Vol. 15  (Suppl 1) , A69-A70
P-021 Multi-center case series of 33 patients with ruptured internal carotid artery blister pseudoaneurysms treated with phosphorylcholine surface-modified flow diverter
Objective Ruptured blister, dissecting, and iatrogenic pseudoaneurysms are rare pathologies that pose significant challenges from a treatment standpoint. Endovascular treatment via flow diversion represents an increasingly popular option; however, drawbacks include the requirement for dual antiplatelet therapy and the potential for thromboembolic complications, particularly acutely in the ruptured setting. The Pipeline Flex Embolization device with Shield technology (PED-Shield) offers a reduced material thrombogenicity via coating with phosphorylcholine, which may aid in the treatment of ruptured internal carotid artery pseudoaneurysms. Methods The authors conducted a multi-institution, retrospective case series to determine the safety and efficacy of PED-Shield in the treatment of ruptured blister, dissecting, and iatrogenic pseudoaneurysms of the internal carotid artery. Clinical, radiographic, treatment, and outcomes data were collected. Results Thirty-three patients were included in the final analysis. Seventeen underwent placement of a single device and 16 underwent placement of two devices. Adjunctive coiling was conducted in two cases. Four patients were maintained on aspirin alone and all others were treated with long-term dual antiplatelet therapy. No thromboembolic complications occurred. Among patients with 3-month follow-up, 93.8% had an modified Rankin Scale score of 0-2. Overall complete occlusion at follow-up was observed in 82.6% of patients. Among patients treated with multiple telescoping devices, complete occlusion was observed in 90.9% of cases, while those treated with a single device demonstrated complete occlusion in 72.7% of cases. Extremely early complete occlusion (observed in less than one month post-operatively) was observed in five patients. Of the five patients, four underwent placement of multiple telescoping devices, while the remaining one was treated with a single device. Conclusions PED-Shield represents a new option for treatment of ruptured blister, dissecting, and iatrogenic pseudoaneurysms of the internal carotid artery, and the presented work represents the largest series to date describing treatment of this pathology with PED-Shield. The reduced material thrombogenicity appears to improve the safety of the PED-Shield device, as our series demonstrated no thromboembolic complications, even among patients treated with only single antiplatelet therapy. The efficacy of the PED-Shield reported in this series, particularly with placement of two devices, demonstrates its potential as a first-line treatment option for these pathologies. Disclosures M. Bounajem: None. E. Joyce: None. J. Scoville: None. J. Seinfeld: 2; C; Medtronic. J. Hoffman: None. J. Grossberg: 1; C; GRA, EMFC, Neurosurgery Catalyst. 4; C; Cognition. V. Waiters: None. A. White: None. J. Nerva: 4; C; Midwest Interventional Systems Inc, Synchron LLC, Bendit Technologies Ltd, Borvo Medical. J. Burkhardt: 2; C; Microvention, Cerenovus, Stryker, Medtronic, Longeviti Neuro Solutions, Q`Apel Medical. D. Tonetti: None. K. El Naamani: None. M. Gooch: 2; C; Stryker. P. Jabbour: 1; C; Medtronic. S. Tjoumakaris: 6; C; Microvention. S. Ortega Gutierrez: 6; C; Stryker, Medtronic, Microvention. M. Levitt: 1; C; Medtronic, Stryker. 2; C; Metis Innovative, Aeaean Advisers, Stereotaxis. 6; C; Prioprio, Hyperion Surgical, Synchron, Fluid Biomed, Cerebrotech. M. Lang: None. W. Ares: None. S. Desai: None. J. Mascitelli: 2; C; Stryker. C. Kilburg: 6; C; Medtronic, Cerenovus. K. Budohoski: None. W. Couldwell: None. B. Gross: 2; C; Medtronic, Microvention, Stryker. R. Grandhi: 6; C; Medtronic, Cerenovus, Balt.
- 30 July 2023
- Published by BMJ
- Vol. 15  (Suppl 1) , A69-A70
Open AccessP-021 Multi-center case series of 33 patients with ruptured internal carotid artery blister pseudoaneurysms treated with phosphorylcholine surface-modified flow diverter
Objective Ruptured blister, dissecting, and iatrogenic pseudoaneurysms are rare pathologies that pose significant challenges from a treatment standpoint. Endovascular treatment via flow diversion represents an increasingly popular option; however, drawbacks include the requirement for dual antiplatelet therapy and the potential for thromboembolic complications, particularly acutely in the ruptured setting. The Pipeline Flex Embolization device with Shield technology (PED-Shield) offers a reduced material thrombogenicity via coating with phosphorylcholine, which may aid in the treatment of ruptured internal carotid artery pseudoaneurysms. Methods The authors conducted a multi-institution, retrospective case series to determine the safety and efficacy of PED-Shield in the treatment of ruptured blister, dissecting, and iatrogenic pseudoaneurysms of the internal carotid artery. Clinical, radiographic, treatment, and outcomes data were collected. Results Thirty-three patients were included in the final analysis. Seventeen underwent placement of a single device and 16 underwent placement of two devices. Adjunctive coiling was conducted in two cases. Four patients were maintained on aspirin alone and all others were treated with long-term dual antiplatelet therapy. No thromboembolic complications occurred. Among patients with 3-month follow-up, 93.8% had an modified Rankin Scale score of 0-2. Overall complete occlusion at follow-up was observed in 82.6% of patients. Among patients treated with multiple telescoping devices, complete occlusion was observed in 90.9% of cases, while those treated with a single device demonstrated complete occlusion in 72.7% of cases. Extremely early complete occlusion (observed in less than one month post-operatively) was observed in five patients. Of the five patients, four underwent placement of multiple telescoping devices, while the remaining one was treated with a single device. Conclusions PED-Shield represents a new option for treatment of ruptured blister, dissecting, and iatrogenic pseudoaneurysms of the internal carotid artery, and the presented work represents the largest series to date describing treatment of this pathology with PED-Shield. The reduced material thrombogenicity appears to improve the safety of the PED-Shield device, as our series demonstrated no thromboembolic complications, even among patients treated with only single antiplatelet therapy. The efficacy of the PED-Shield reported in this series, particularly with placement of two devices, demonstrates its potential as a first-line treatment option for these pathologies. Disclosures M. Bounajem: None. E. Joyce: None. J. Scoville: None. J. Seinfeld: 2; C; Medtronic. J. Hoffman: None. J. Grossberg: 1; C; GRA, EMFC, Neurosurgery Catalyst. 4; C; Cognition. V. Waiters: None. A. White: None. J. Nerva: 4; C; Midwest Interventional Systems Inc, Synchron LLC, Bendit Technologies Ltd, Borvo Medical. J. Burkhardt: 2; C; Microvention, Cerenovus, Stryker, Medtronic, Longeviti Neuro Solutions, Q`Apel Medical. D. Tonetti: None. K. El Naamani: None. M. Gooch: 2; C; Stryker. P. Jabbour: 1; C; Medtronic. S. Tjoumakaris: 6; C; Microvention. S. Ortega Gutierrez: 6; C; Stryker, Medtronic, Microvention. M. Levitt: 1; C; Medtronic, Stryker. 2; C; Metis Innovative, Aeaean Advisers, Stereotaxis. 6; C; Prioprio, Hyperion Surgical, Synchron, Fluid Biomed, Cerebrotech. M. Lang: None. W. Ares: None. S. Desai: None. J. Mascitelli: 2; C; Stryker. C. Kilburg: 6; C; Medtronic, Cerenovus. K. Budohoski: None. W. Couldwell: None. B. Gross: 2; C; Medtronic, Microvention, Stryker. R. Grandhi: 6; C; Medtronic, Cerenovus, Balt.
- 16 January 2023
- Published by Wolters Kluwer Health in Operative Neurosurgery
- Vol. 24  (4) , e255-e263
Technical Nuances and Outcomes of Telescoping Pipeline Flow Diverters: A Multicenter Study
BACKGROUND: “Telescoping” multiple overlapping Pipeline Embolization Devices (PEDs; Medtronic) has increased their utility by allowing for more impermeable coverage and providing the ability to off-set landing zone sites and extend treatment constructs. OBJECTIVE: To consider the technical nuances and challenges of telescoping PEDs for the treatment of intracranial aneurysms. METHODS: Databases from 3 U.S. academic neurovascular centers were retrospectively queried to identify patients with intracranial aneurysms treated with multiple PED constructs. Data on patient and aneurysm characteristics, as well as outcomes including Raymond-Roy occlusion classification, modified Rankin Scale score, and complications, were gathered. RESULTS: Forty-six patients had 48 intracranial aneurysms treated, including 16 (33%) in whom placement of telescoping PEDs was planned. Fourteen (30%) patients presented with a ruptured aneurysm. Twenty-one aneurysms (44%) were treated with proximal extension, 13 (27%) with distal extension, and 14 (29%) with PED placement inside one another. Thirty (70%) patients had complete aneurysm occlusion at follow-up. Two (4%) patients had to be retreated. Three patients with unruptured and 1 with ruptured aneurysm had a permanent intraprocedural complication. We present descriptive cases illustrating PEDs that were placed inside one another, proximally, distally, and to improve wall apposition because of vessel tortuosity. CONCLUSION: Our data indicate a higher than expected complication rate that is likely because of the technical complexity of these cases. The case illustrations presented demonstrate the indications and challenging aspects of telescoping PEDs.
- 16 January 2023
- Published by Wolters Kluwer Health in Operative Neurosurgery
- Vol. 24  (4) , e255-e263
Technical Nuances and Outcomes of Telescoping Pipeline Flow Diverters: A Multicenter Study
BACKGROUND: “Telescoping” multiple overlapping Pipeline Embolization Devices (PEDs; Medtronic) has increased their utility by allowing for more impermeable coverage and providing the ability to off-set landing zone sites and extend treatment constructs. OBJECTIVE: To consider the technical nuances and challenges of telescoping PEDs for the treatment of intracranial aneurysms. METHODS: Databases from 3 U.S. academic neurovascular centers were retrospectively queried to identify patients with intracranial aneurysms treated with multiple PED constructs. Data on patient and aneurysm characteristics, as well as outcomes including Raymond-Roy occlusion classification, modified Rankin Scale score, and complications, were gathered. RESULTS: Forty-six patients had 48 intracranial aneurysms treated, including 16 (33%) in whom placement of telescoping PEDs was planned. Fourteen (30%) patients presented with a ruptured aneurysm. Twenty-one aneurysms (44%) were treated with proximal extension, 13 (27%) with distal extension, and 14 (29%) with PED placement inside one another. Thirty (70%) patients had complete aneurysm occlusion at follow-up. Two (4%) patients had to be retreated. Three patients with unruptured and 1 with ruptured aneurysm had a permanent intraprocedural complication. We present descriptive cases illustrating PEDs that were placed inside one another, proximally, distally, and to improve wall apposition because of vessel tortuosity. CONCLUSION: Our data indicate a higher than expected complication rate that is likely because of the technical complexity of these cases. The case illustrations presented demonstrate the indications and challenging aspects of telescoping PEDs.
- Open Access
- 30 May 2022
- Published by MDPI AG in Journal of Personalized Medicine
- Vol. 12  (6) , 904
Untangling the Modern Treatment Paradigm for Unruptured Brain Arteriovenous Malformations
Brain arteriovenous malformations (AVMs) often present treatment challenges. Patients with unruptured AVMs must consider not only whether they want to be treated, but what treatment modality they would prefer. Vascular neurosurgeons, neurointerventional surgeons, and stereotactic radiosurgeons must in turn guide their patients through the most appropriate treatment course considering the risk of AVM rupture, an individual AVM’s characteristics, and patient preferences. In this review we will look at how the clinical trial “A Randomized Trial of Unruptured Brain Arteriovenous Malformations (ARUBA)” has influenced the approach to unruptured brain AVMs and the treatment modalities available to clinicians to deal with these formidable lesions.
- 30 May 2022
- Published by MDPI AG in Journal of Personalized Medicine
- Vol. 12  (6) , 904
Open AccessUntangling the Modern Treatment Paradigm for Unruptured Brain Arteriovenous Malformations
Brain arteriovenous malformations (AVMs) often present treatment challenges. Patients with unruptured AVMs must consider not only whether they want to be treated, but what treatment modality they would prefer. Vascular neurosurgeons, neurointerventional surgeons, and stereotactic radiosurgeons must in turn guide their patients through the most appropriate treatment course considering the risk of AVM rupture, an individual AVM’s characteristics, and patient preferences. In this review we will look at how the clinical trial “A Randomized Trial of Unruptured Brain Arteriovenous Malformations (ARUBA)” has influenced the approach to unruptured brain AVMs and the treatment modalities available to clinicians to deal with these formidable lesions.
- 12 May 2022
- Published by American Society of Neuroradiology (ASNR) in American Journal of Neuroradiology
- Vol. 43  (6) , 913-918
Stroke Recurrence in Children with Vertebral Artery Dissecting Aneurysm
BACKGROUND AND PURPOSE: Pediatric vertebral artery dissecting aneurysm is a subtype of vertebral artery dissection that can be challenging to diagnose and may be associated with stroke recurrence. This study examines the presenting features, clinical outcomes, and recurrence risk in a cohort of children with vertebral artery dissection, comparing those with aneurysms with those without. MATERIALS AND METHODS: The medical records of children evaluated for vertebral artery dissection were retrospectively reviewed for neurologic presentation, treatment, stroke recurrence, and angiographic appearance of dissection. Cohort patients were categorized into 2 groups based on the presence or absence of a vertebral artery dissecting aneurysm and compared via the Fisher exact test, Student t test, and log-rank analyses. P < .05 was deemed statistically significant. RESULTS: Thirty-two patients met the inclusion criteria, including 13 with vertebral artery dissecting aneurysms. Five cases of vertebral artery dissecting aneurysm were missed on the initial evaluation and diagnosed retrospectively. All patients received antiplatelet or anticoagulation therapy at the time of diagnosis. Children in the vertebral artery dissecting aneurysm group were more likely to present with stroke (P = .059), present at a younger age (P < .001), and have recurrent stroke (P < .001) compared with the group of children with vertebral artery dissection without an aneurysm. After surgery, no patients with vertebral artery dissecting aneurysm experienced recurrent stroke (P = .02). CONCLUSIONS: Vertebral artery dissecting aneurysm is often missed on the initial diagnostic evaluation of children presenting with stroke. In children with vertebral artery dissection, the presence of an aneurysm is associated with stroke presentation at a younger age and stroke recurrence.
- 12 May 2022
- Published by American Society of Neuroradiology (ASNR) in American Journal of Neuroradiology
- Vol. 43  (6) , 913-918
Stroke Recurrence in Children with Vertebral Artery Dissecting Aneurysm
BACKGROUND AND PURPOSE: Pediatric vertebral artery dissecting aneurysm is a subtype of vertebral artery dissection that can be challenging to diagnose and may be associated with stroke recurrence. This study examines the presenting features, clinical outcomes, and recurrence risk in a cohort of children with vertebral artery dissection, comparing those with aneurysms with those without. MATERIALS AND METHODS: The medical records of children evaluated for vertebral artery dissection were retrospectively reviewed for neurologic presentation, treatment, stroke recurrence, and angiographic appearance of dissection. Cohort patients were categorized into 2 groups based on the presence or absence of a vertebral artery dissecting aneurysm and compared via the Fisher exact test, Student t test, and log-rank analyses. P < .05 was deemed statistically significant. RESULTS: Thirty-two patients met the inclusion criteria, including 13 with vertebral artery dissecting aneurysms. Five cases of vertebral artery dissecting aneurysm were missed on the initial evaluation and diagnosed retrospectively. All patients received antiplatelet or anticoagulation therapy at the time of diagnosis. Children in the vertebral artery dissecting aneurysm group were more likely to present with stroke (P = .059), present at a younger age (P < .001), and have recurrent stroke (P < .001) compared with the group of children with vertebral artery dissection without an aneurysm. After surgery, no patients with vertebral artery dissecting aneurysm experienced recurrent stroke (P = .02). CONCLUSIONS: Vertebral artery dissecting aneurysm is often missed on the initial diagnostic evaluation of children presenting with stroke. In children with vertebral artery dissection, the presence of an aneurysm is associated with stroke presentation at a younger age and stroke recurrence.
- 8 April 2014
- Published by Wolters Kluwer Health in Neurology
- Vol. 82  (10_supplem)
The Association and Treatment of Distal PICA Aneurysms with Posterior Fossa Arteriovenous Malformation: A Case Series (P3.115)
- 8 April 2014
- Published by Wolters Kluwer Health in Neurology
- Vol. 82  (10_supplem)
The Association and Treatment of Distal PICA Aneurysms with Posterior Fossa Arteriovenous Malformation: A Case Series (P3.115)